Home›Stock Screener›Ind Swift Laboratories

Ind Swift Laboratories Share Price Today | Stock Price & Ind Swift Laboratories Share Screener

INDSWFTLAB Pharmaceuticals & Biotechnology
Live Share Price NSE
₹336.75
▲ 4.85 (1.46%)
2026-11-18 00:00:00
Live Share Price BSE
₹335.90
▲ 3.40 (1.02%)
2026-11-18 00:00:00

As of November 18, 2026, the live Ind Swift Laboratories share price (NSE: INDSWFTLAB) is ₹336.75 on NSE and ₹335.90 on BSE, up 1.46% from the previous close, with shares trading between ₹325.00 and ₹339.25 in today's trading session, and a 52-week range of ₹88.15–₹413.10. Track Ind Swift Laboratories marketcap in USD to gauge the company's total market size. Use the Ind Swift Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ind Swift Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹172 and net income of ₹15, with EBITDA of ₹18, an operating margin of 9.0% and a profit margin of 8.7%.

Ind Swift Laboratories Market Cap ₹3,034.96 Cr.
INDSWFTLAB P/E Ratio (TTM) 37.60
Ind Swift Laboratories P/B Ratio 2.13
EPS (TTM) ₹5.16
Dividend Yield -
Debt to Equity 0.01
INDSWFTLAB 52 Week High ₹413.10
Ind Swift Laboratories 52 Week Low ₹88.15
Operating Margin 9.00%
Profit Margin 8.72%
INDSWFTLAB Revenue (TTM) ₹172.00
EBITDA ₹18.00
Net Income ₹15.00
Total Assets ₹1,673.00
Total Equity ₹1,384.00

Ind Swift Laboratories Share Price Chart

Track the current stock price of Ind Swift Laboratories with an interactive chart. Analyse INDSWFTLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ind Swift Laboratories stock quote in one place.

The quote of ₹336.75 sits between the 52-week low of ₹88.15 and the 52-week high of ₹413.10, and the latest session moved 1.46% from the previous close.

Ind Swift Laboratories Company Profile - Fundamental Screener

Screen Ind Swift Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for INDSWFTLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE915B01019.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE915B01019

Ind Swift Laboratories Balance Sheet Screener

Screen INDSWFTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,673, up from ₹1,438 in 2025.

Latest statistics put total assets at ₹1,673 and shareholder funds at ₹1,384, with a leverage ratio of 0.01.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,673 1,438 1,165 1,824 1,801 1,818 1,870 1,924 2,023 2,138
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 304 273 8 588 630 753 843 914 934 1,042

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 32 45 12 771 866 901 906 980 534 601
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,384 1,173 931 682 601 603 641 588 553 531
Share Capital 87 69 59 60 60 60 60 48 46 46
Reserves & Surplus 1,297 1,030 872 622 541 544 581 540 507 486

Ind Swift Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Ind Swift Laboratories income statement and profit fundamentals. Analyze INDSWFTLAB quarterly results. Ind Swift Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹172 and net profit was ₹15, equal to earnings per unit of ₹1.81, at an operating margin of 9%.

In that period expenses were ₹154, interest cost ₹-2 and tax ₹-3. The next period listed, 2026-Jun, shows revenue of ₹199 and net profit of ₹25.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 172 199 248 359 167 171 178 987 44 25 145 315 316 297 295
Expenses 154 158 196 147 149 151 153 437 43 24 136 267 250 224 236

Operating Costs and Margins

EBITDA 18 41 53 211 18 19 26 549 1 1 9 47 66 73 59
Operating Profit % 9.00% 17.00% 19.00% -7.00% 2.00% 5.00% -1.00% 17.00% -29.00% -99.00% -6.00% 12.00% 19.00% 23.00% 18.00%
Depreciation 8 8 8 7 7 7 9 20 0 0 6 9 14 13 14
Interest -2 1 1 -27 1 2 1 3 0 0 10 22 20 21 21

Profit and Earnings

Profit Before Tax 12 33 43 231 10 10 16 527 1 1 -7 16 32 39 24
Tax -3 8 9 8 2 2 7 33 0 0 -1 41 14 7 5
Net Profit 15 25 34 222 9 8 10 494 1 0 -6 -25 17 32 19
EPS 1.81 2.84 3.94 32.96 1.28 1.00 1.17 83.55 0.16 0.07 -0.82 -4.25 2.92 5.36 3.29

Ind Swift Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen INDSWFTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹68, and net cash flow was an inflow of ₹5.

Over the same period, investing activities used ₹69 and financing activities provided ₹142.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -68 -29 -163 195 150 135 125 -64 73 96
Investing Activities -69 -113 -104 -13 5 -10 -9 -13 -17 -31

Financing and Net Cash

Financing Activities 142 72 699 -186 -141 -124 -133 100 -62 -69
Net Cash Flow 5 -69 432 -4 14 1 -17 23 -6 -4

Ind Swift Laboratories Shareholding Pattern Screener

See Ind Swift Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Ind Swift Laboratories promoter holding and ownership changes for INDSWFTLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Feb, promoters held 43.06%, foreign institutions 13.80%, domestic institutions 0.16% and the public 32.97%, spread across 40,404 shareholders.

The shareholder count was 40,404 in 2026-Feb, compared with 39,222 in 2026-Mar.

Item 2026-Feb 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Jul 2025-Aug

Promoter Holding

Promoter Holding 43.06% 42.99% 42.93% 42.93% 40.94% 40.94% 36.77% 39.50%

Institutional Investors

FII Holding 13.80% 13.88% 10.70% 10.78% 3.07% 4.27% 0.00% 0.00%
DII Holding 0.16% 0.00% 0.17% 0.20% 0.91% 0.91% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 32.97% 32.90% 34.45% 35.40% 37.61% 41.36% 35.11% 34.75%
Other Holding 10.01% 10.22% 11.75% 10.69% 17.46% 12.51% 28.12% 25.76%
Shareholder Count 40,404 39,222 40,881 42,112 28,190 28,709 28,539 28,892

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ind Swift Laboratories. Ind Swift Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Ind Swift Laboratories.

Ind Swift Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Ind Swift Laboratories stock. Check INDSWFTLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Ind Swift Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Ind Swift Laboratories Market Events Screener - Corporate Actions

Get Ind Swift Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ind Swift Laboratories stock events that may affect INDSWFTLAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 29, 2026, with a record date of October 29, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 10, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-29 2026-10-29 Quarterly Result Announcement NA 2.68%
2026-09-30 2026-09-30 Annual General Meeting NA 12.27%
2026-08-10 2026-08-10 Quarterly Result Announcement NA 1.62%
2026-08-05 2026-08-05 Extraordinary General Meeting NA -1.94%
2026-05-28 2026-05-28 Quarterly Result Announcement NA -0.70%
2026-01-31 2026-01-31 Quarterly Result Announcement NA 6.25%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 1.83%
2025-09-29 2025-09-29 Annual General Meeting NA 1.99%
2025-08-14 2025-08-14 Merger - Demerger 100:15 0.00%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -1.61%
2025-08-11 2025-08-11 Quarterly Result Announcement NA -4.59%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 7.93%
2025-02-22 2025-02-22 Extraordinary General Meeting NA -12.05%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -11.38%
2024-11-11 2024-11-11 Quarterly Result Announcement NA -2.34%

Ind Swift Laboratories Competitors Screener - Peer Stocks Comparison

Screen INDSWFTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Ind Swift Laboratories Company Announcements - News & Reports Screener

Screen INDSWFTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 13, 2026.

The next most recent announcements are dated November 4, 2026 and November 4, 2026.

Date Update Actions
2026-11-13 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-04 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-04 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-03 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-03 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-10-30 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-29 NIL STATEMENT ON DEVIATION OR VARIATION OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 7000000 FULLY CONVERTIBLE WARRANTS -
2026-10-29 NIL STATEMENT ON DEVIATION OR VARIATION OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE OF 26000000 FULLY CONVERTIBLE WARRANTS -
2026-10-29 Financial Results For The Quarter And Six Months Ended September 29 2026 -
2026-10-29 Board Meeting Outcome for Outcome Of Board Meeting Dated October 29 2026 -
2026-10-15 Board Meeting Intimation for Meeting To Be Held On October 29 2026. -
2026-10-12 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-12 Disclosures Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011 -
2026-10-08 Announcement under Regulation 30 (LODR)-Conversion of Securities -
2026-10-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-05 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-28 Intimation To The Shareholders Of Physical Securities Pursuant To SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 Dated May 07 2024 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹336.75, within a 52-week range of ₹88.15 to ₹413.10. The P/E ratio is 37.60 and the P/B ratio is 2.13, with earnings per unit of ₹5.16. Market capitalisation stands at ₹3,034.96 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.